Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Kuilman

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Cell|January 25, 2020
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity ThresholdDavid W Vredevoogd, Thomas Kuilman, Maarten A Ligtenberg, et al.
Cell|July 16, 2019
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity ThresholdDavid W Vredevoogd, Thomas Kuilman, Maarten A Ligtenberg, et al.
Nature Medicine|January 16, 2018
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitorsJulia Boshuizen, Louise A Koopman, Oscar Krijgsman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2021
Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4Oscar Krijgsman, Kristel Kemper, Julia Boshuizen, et al.
Molecular Oncology|April 1, 2015
Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platformsPhilip C Schouten, Anita Grigoriadis, Thomas Kuilman, et al.
Cell Reports. Medicine|February 22, 2023
An adverse tumor-protective effect of IDO1 inhibitionJuliana C N Kenski, Xinyao Huang, David W Vredevoogd, et al.
Nature Cell Biology|June 25, 2013
TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cellsAnnamaria Biroccio, Julien Cherfils-Vicini, Adeline Augereau, et al.
Nature Communications|January 14, 2025
Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsiesThomas Kuilman, Deborah S Schrikkema, Jules Gadiot, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Cell|January 25, 2020
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity ThresholdDavid W Vredevoogd, Thomas Kuilman, Maarten A Ligtenberg, et al.
Cell|July 16, 2019
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity ThresholdDavid W Vredevoogd, Thomas Kuilman, Maarten A Ligtenberg, et al.
Nature Medicine|January 16, 2018
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitorsJulia Boshuizen, Louise A Koopman, Oscar Krijgsman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2021
Predictive Immune-Checkpoint Blockade Classifiers Identify Tumors Responding to Inhibition of PD-1 and/or CTLA-4Oscar Krijgsman, Kristel Kemper, Julia Boshuizen, et al.
Molecular Oncology|April 1, 2015
Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platformsPhilip C Schouten, Anita Grigoriadis, Thomas Kuilman, et al.
Cell Reports. Medicine|February 22, 2023
An adverse tumor-protective effect of IDO1 inhibitionJuliana C N Kenski, Xinyao Huang, David W Vredevoogd, et al.
Nature Cell Biology|June 25, 2013
TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cellsAnnamaria Biroccio, Julien Cherfils-Vicini, Adeline Augereau, et al.
Nature Communications|January 14, 2025
Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsiesThomas Kuilman, Deborah S Schrikkema, Jules Gadiot, et al.
Pageof 3